Metropolis Healthcare Ltd (METROPOLIS) — shareholding pattern, promoter holding, financials and share price
About Metropolis Healthcare Ltd (METROPOLIS)
Metropolis Healthcare Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as METROPOLIS and on the BSE under scrip code 542650. Its ISIN is INE112L01020.
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
Metropolis Healthcare Limited is a pan-India clinical diagnostics company operating a large hub-and-spoke laboratory network, offering routine to super-specialty tests, genomics, B2C and B2B services, preventive wellness (TruHealth) and institutional clinical research support across India and selected international markets.
Q3 FY26 organic revenue grew 15% to INR 371 crore with EBITDA of INR 93 crore and margin expansion to 25%, while Group revenue grew 26% to INR 406 crore; PAT excluding exceptional items rose meaningfully, reflecting improving mix, productivity initiatives and economies of scale.
Listed peers in Healthcare Service Provider: Vijaya Diagnostic Centre Ltd, Thyrocare Technologies Ltd, Nephrocare Health Services Ltd, Krsnaa Diagnostics Ltd, Suraksha Diagnostic Ltd, One Global Service Provider Ltd.
Valuation & Returns
10 Jul 2026At ₹566 a share on 10 Jul 2026, Metropolis Healthcare Ltd (METROPOLIS) was valued at a price-to-earnings ratio of 61.38x against an industry P/E of 61.73x and a price-to-book of 8.82x on a book value of ₹64.2 per share as of Mar 2025. Solomo computes return on equity of 14.36% and return on capital employed of 18.48% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 61.38x
- Industry P/E
- 61.73x
- P/B
- 8.82x
- EPS (TTM)
- ₹9.22
- Book value / share
- ₹64.2
- ROE
- 14.36%
- ROCE
- 18.48%
- ROA
- 10.24%
- Debt / equity
- 0.15x
- Dividend yield
- 0.88%
- EBITDA margin
- 25.36%
- 52-week range
- ₹413 – ₹599.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Metropolis Healthcare Ltd (METROPOLIS) reported revenue of ₹1,646 crore, net profit of ₹191 crore and earnings per share of ₹9.17. That compares with revenue of ₹1,331 crore and net profit of ₹146 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹425 crore and net profit ₹51 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 |
| Net profit (₹ cr) | 215 | 143 | 128 | 146 | 191 |
| EPS (₹) | 10.46 | 6.98 | 6.24 | 7 | 9.17 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 12.83% | 1.69% | 10.23% |
| Profit growth | 2.18% | -14.48% | 13.27% |
| Stock price CAGR | -4% | 17% | 17% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 48.86% of Metropolis Healthcare Ltd (METROPOLIS) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 11.03% and domestic institutional investors (DII) hold 35.12%. Promoters have pledged 1.2% of their holding. Market capitalisation was ₹11,735 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2019.
Largest disclosed public shareholders in Jun 2026: Hdfc Mutual Fund - Hdfc Focused Fund 9.66%, Franklin India Small Cap Fund 4.24%, Kotak Small Cap Fund 3.79%, Uti-Large Cap Fund 3.72%, Tata Business Cycle Fund 2.84%, Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund 2.21%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 48.86% | 1.2% | 11.03% | 35.12% | 51.14% |
| Mar 2026 | 48.87% | 1.2% | 10.43% | 35.79% | 51.13% |
| Dec 2025 | 48.88% | 1.2% | 11.69% | 34.73% | 51.12% |
| Sep 2025 | 48.89% | 1.2% | 12.52% | 33.1% | 51.11% |
| Jun 2025 | 48.89% | 1.2% | 12.83% | 32.4% | 51.11% |
| Mar 2025 | 48.9% | 1.2% | 15.29% | 30.3% | 51.1% |
| Dec 2024 | 49.4% | 1.2% | 16.73% | 30% | 50.6% |
| Sep 2024 | 49.43% | 1.2% | 18.56% | 28.02% | 50.57% |